[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asthma-copd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asthma-copd":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,67,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100595317","effect-of-spacer-use-on-exacerbation-risk-in-high-risk-older-adults-with-chronic-airway-diseases-receiving-triple-therapy-100595317",false,"NCT07030881","Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy","Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥65 years, no gender restriction;\n2. Confirmed diagnosis of chronic obstructive pulmonary disease (COPD) based on GOLD criteria or bronchial asthma based on GINA criteria;\n3. Currently on stable treatment with fixed-dose combination ICS\u002FLABA\u002FLAMA via pMDI for ≥4 weeks;\n4. History of any of the following in the past 12 months:\n\n   1. ≥1 hospitalization due to exacerbation, or\n   2. ≥2 moderate exacerbations requiring systemic corticosteroids and\u002For antibiotics;\n5. Able to complete inhalation technique training and demonstrate basic communication and device-handling abilities;\n6. Provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Use of other inhalation devices as primary therapy (e.g., DPI, SMI, or nebulizer);\n2. Regular use of a spacer device for ≥3 weeks within 3 months prior to enrollment;\n3. Current or recent (within 4 weeks) acute exacerbation not fully resolved;\n4. Severe cognitive impairment (MMSE score \\\u003C18);\n5. Presence of severe systemic comorbidities (e.g., end-stage malignancy, advanced heart failure, hepatic or renal failure);\n6. Participation in another interventional clinical trial;\n7. Inability to use a mouthpiece-based spacer (e.g., structural oral\u002Ffacial abnormalities, severe anxiety);\n8. Known allergy or hypersensitivity to spacer device materials.","ALL","65 Years",{"count":19,"type":20},380,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study evaluates whether adding a spacer device to triple inhaled therapy (ICS\u002FLABA\u002FLAMA via pMDI) can reduce acute exacerbations in elderly patients (≥65 years) with stable chronic airway diseases (COPD or asthma) who are classified as high-risk based on GOLD or GINA guidelines. High risk is defined as ≥1 hospitalization or ≥2 moderate exacerbations in the past 12 months.\n\nDespite receiving triple inhaled therapy, these patients often have poor inhaler technique due to age-related limitations. A spacer may improve drug delivery, adherence, and reduce local side effects.\n\nIn this multicenter, open-label, randomized controlled trial, 380 participants will be assigned to standard therapy with or without a valved spacer. The primary outcome is the 3-month incidence of moderate-to-severe exacerbations. Secondary outcomes include lung function, adherence, inhalation technique, side effects, and patient satisfaction.",[26],"Asthma, COPD","RECRUITING","2026-06-23",{"date":30,"type":31},"2026-06-26","ACTUAL",{"date":33,"type":31},"2025-06-17",{"date":35,"type":20},"2027-06-30",{"name":37,"class":38},"First Affiliated Hospital of Ningbo University","NETWORK",9,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100627358","oscillometry-and-machine-learning-approaches-100627358","NCT07447596","Oscillometry and Machine Learning Approaches","Feasibility Study of Forced Oscillometry in the Prediction of Chronic Respiratory Diseases Using Machine Learning Approaches","Inclusion Criteria:\n\n* 18 - 90 years\n* Spirometry available\n* Confirmed clinical diagnosis of COPD, asthma, interstitial lung disease according to national or international guidelines\n\nExclusion Criteria:\n\n* Acute respiratory infection",true,"18 Years","99 Years",{"count":51,"type":20},50,"OBSERVATIONAL","Unicentric retrospective study designed to analyses the performance of various machine learning approaches to predict patterns of chronic respiratory diseases such as asthma, based mainly on clinical information and respiratory spirometry\u002Foscillometry.",[55],"Asthma COPD","2026-02-26",{"date":58,"type":31},"2026-03-03",{"date":60,"type":31},"2025-10-15",{"date":62,"type":20},"2026-09-01",{"name":64,"class":65},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","OTHER",1,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":66},"100557458","clinical-utility-of-portable-dynamic-chest-x-ray-ddr-in-the-icu-100557458","NCT06538376","Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU","Clinical Utility of Portable Dynamic Chest X-Ray (DDR) in the ICU: Clinical Trial to Demonstrate the Feasibility of Deploying DDR Technology in the ICU - A Study to Prove Its Increased Diagnostic Value","Inclusion Criteria: Participants must meet all the following inclusion criteria to participate in this study:\n\n* Adults (at least 18 years of age) including both intubated\u002Fventilated and non-intubated patients\n* Likely to have pathology related to either, abnormal diaphragmatic excursion and lung aeration, pulmonary perfusion, increased lung water content or all the above, as well as for cricopharyngeal dysfunction\u002Fswallowing difficulties at risk for aspiration.\n* The subject or a legally authorized representative has provided written informed consent.\n\nExclusion Criteria: Candidates meeting any of the exclusion criteria at baseline will be excluded from study participation. These criteria are:\n\n* Special populations, including women with known pregnancy, prisoners, or institutionalized individuals\n* Patients where additional radiation is clinically contraindicated\n* Care team does not provide assent for approaching patient\u002Fsurrogate\n* For women of child-bearing potential, defined as premenopausal women, a pregnancy test will be administered to determine pregnancy status and confirm eligibility for the study. A pregnancy test will NOT be administered to women who are post-menopausal or have documentation of surgical sterilization.",{"count":75,"type":20},230,[23],"Dynamic digital radiography (DDR) is a new advanced version of chest radiography that captures dynamic images at a rate of 15 frames per second. It is coupled with an analytical software that allows it to provide more advanced measures of lung motion, ventilation, and perfusion compared to traditional chest radiography. While implementation of DDR fixed machines are beginning elsewhere in the US, this trial involves the first applications of an FDA-approved portable DDR machine, for use at the bedside in the ICU.\n\nThe goal of this clinical trial is to determine the feasibility and safety of portable DDR technology in the ICU, as well as to evaluate the improved clinical diagnostic value of the portable DDR system over current standards of care.\n\nParticipants will receive one to three sets of DDR images, which will then be compared to their clinical gold standard exams (such as chest x-rays, CTs, or VQ scans) to assess and improve the precision and accuracy of measurements such as diaphragmatic motion, lung movement, and perfusion.",[79,80,81,82,83,84,85,86,55,87,88,89,90,91],"Pulmonary Edema","Pneumonia","Atelectasis","Pleural Effusion","Acute Rejection of Lung Transplant (Disorder)","Airway Obstruction","Rib Fractures","Acute Copd Exacerbation","Pulmonary Embolism","Hemothorax","Pneumothorax","Mesothelioma","Diaphragmatic Paralysis","2025-10-28",{"date":94,"type":31},"2025-10-29",{"date":96,"type":31},"2023-12-12",{"date":98,"type":20},"2027-11",{"name":100,"class":65},"Brigham and Women's Hospital",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":21,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100559393","fcv-vs-vcv-in-obstructive-and-asthmatic-patients-100559393","NCT06563544","FCV Vs VCV in Obstructive and Asthmatic Patients","Flow Versus Volume-Controlled Ventilation in Intubated Obstructive and Asthmatic Patients","Inclusion Criteria:\n\n* 18 years or older;\n* Provided written informed consent;\n* Undergoing controlled mechanical ventilation via an endotracheal tube;\n* Reason for intubation being exacerbation of asthma or COPD;\n* Intubated ≤72 hours\n\nExclusion Criteria:\n\n* Severe sputum stasis or production requiring frequent bronchial suctioning (more than 5 times per nurse shift)\n* Untreated pneumothorax (i.e. no pleural drainage)\n* Hemodynamic instability defined as a mean arterial pressure below 60mmHg not responding to fluids and\u002For vasopressors or a noradrenalin dose \\>0.5mcrg\u002Fkg\u002Fmin\n* High (\\>15 mmHg) or instable (an increase in sedation or osmotherapy is required) intracranial pressure\n* An inner tube diameter of 6mm or less\n* Anticipating withdrawal of life support and\u002For shift to palliation as the goal of care\n* Inability to perform adequate electrical impedance tomography (EIT) measurements with, e.g.:\n\n  * Have a thorax circumference inappropriate for EIT-belt\n  * Thoracic wounds, bandages or deformities preventing adequate fit of EIT-belt\n  * Recent (\\\u003C7 days) pulmonary surgery including pneumonectomy, lobectomy or lung transplantation\n  * ICD device present (potential interference with proper functioning of the EIT device and ICD device)\n  * Excessive subcutaneous emphysema\n* Contra-indications for nasogastric tube or inability to perform adequate transpulmonary pressure measurements with, e.g.:\n\n  * Recent esophageal surgery\n  * Prior esophagectomy\n  * Known presence of esophageal varices\n  * Severe bleeding disorders","100 Years",{"count":110,"type":20},10,[23],"The goal of this physiological pilot study with a randomized crossover design is to study the effect of Flow-controlled ventilation (FCV) on the minute volume compared to Volume-controlled ventilation (VCV) in intubated patients with an exacerbation of their asthma or COPD.\n\nOur hypothesis is that FCV will results in a lower minute volume compared to VCV in this patient category.\n\nPatients will be randomized between two ventilation sequences, namely 90 minutes of FCV followed by 90 minutes of VCV or vice versa.",[114,115,55],"Obstructive Pulmonary Disease","Mechanical Ventilation Pressure High","2024-10-16",{"date":118,"type":31},"2024-10-18",{"date":120,"type":20},"2024-10",{"date":122,"type":20},"2027-10",{"name":124,"class":65},"Erasmus Medical Center",2]